Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
Public ClinicalTrials.gov record NCT00066846. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin®) Plus 5-Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancers That Have Progressed After Standard Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Bevacizumab may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as fluorouracil and leucovorin use different ways to stop tumor cells from dividing so they stop growing or die. Combining bevacizumab with fluorouracil and leucovorin may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining bevacizumab with fluorouracil and leucovorin in treating patients who have locally advanced or metastatic stage IV colorectal cancer that has progressed after standard chemotherapy.
Study identification
- NCT ID
- NCT00066846
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2003 (Type not available)
- Primary completion
- Not listed
- Completion
- Jul 2007 (Actual)
- Last update posted
- Jun 20, 2013
2003 – 2007
United States locations
- U.S. sites
- 33
- U.S. states
- 26
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Alaska Medical Center | Anchorage | Alaska | 99519-6604 | — |
| Jonsson Comprehensive Cancer Center, UCLA | Los Angeles | California | 90024 | — |
| USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles | California | 90033-0804 | — |
| University of Colorado Cancer Center at University of Colorado Health Sciences Center | Aurora | Colorado | 80010 | — |
| Yale Comprehensive Cancer Center | New Haven | Connecticut | 06520-8028 | — |
| Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| CCOP - Atlanta Regional | Atlanta | Georgia | 30342-1701 | — |
| Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago | Illinois | 60611 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242-1009 | — |
| Siouxland Hematology-Oncology | Sioux City | Iowa | 51101-1733 | — |
| CCOP - Wichita | Wichita | Kansas | 67214-3882 | — |
| Cancer Care of Maine | Bangor | Maine | 04401 | — |
| Saint Joseph Mercy Health System | Ann Arbor | Michigan | 48106 | — |
| St. Mary's/Duluth Clinic Cancer Center | Duluth | Minnesota | 55805 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216-4505 | — |
| CCOP - Montana Cancer Consortium | Billings | Montana | 59101 | — |
| Southern Nevada Cancer Research Foundation | Las Vegas | Nevada | 89106 | — |
| Norris Cotton Cancer Center | Lebanon | New Hampshire | 03756-0002 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263-0001 | — |
| New York Weill Cornell Cancer Center at Cornell University | New York | New York | 10021 | — |
| Duke Comprehensive Cancer Center | Durham | North Carolina | 27710 | — |
| Comprehensive Cancer Center at Wake Forest University | Winston-Salem | North Carolina | 27157-1082 | — |
| Meritcare Roger Maris Cancer Center | Fargo | North Dakota | 58122 | — |
| Ireland Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Kimmel Cancer Center of Thomas Jefferson University - Philadelphia | Philadelphia | Pennsylvania | 19107-5541 | — |
| Sioux Valley Clinics - Oncology | Sioux Falls | South Dakota | 57104 | — |
| Fletcher Allen Health Care - University Health Center Campus | Burlington | Vermont | 05401 | — |
| Massey Cancer Center | Richmond | Virginia | 23298-0037 | — |
| CCOP - Virginia Mason Research Center | Seattle | Washington | 98101 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00066846, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 20, 2013 · Synced Nov 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00066846 live on ClinicalTrials.gov.